Medigen Vaccine Biologics Cash Flow Quality Index

Latest as of June 2026: -4.08x

Medigen Vaccine Biologics cash flow quality index. Medigen Vaccine Biologics (6547) has a Cash Flow Quality Index of -4.08x as of June 2026. Operating cash flow of NT$-91.20 Million is below net income of NT$22.35 Million, suggesting accrual-heavy earnings not yet converted to cash. See Medigen Vaccine Biologics financial flexibility index to measure the company's free cash flow as a share of total liabilities.

Cash Flow Quality Index

-4.08x
Operating CF / Net Income

Operating Cash Flow

NT$-91.20 Million
TWD

Net Income

NT$22.35 Million
TWD

Data as of

Jun 2026
Most recent filing

Cash Flow Quality Index of Medigen Vaccine Biologics (2021–2021)

Cash flow quality index of Medigen Vaccine Biologics from 2021 to 2021. Historical Cash Flow Quality Index for Medigen Vaccine Biologics across 1 annual periods. Values consistently above 1.0x indicate high-quality earnings. Explore 6547 debt coverage from operations to assess how comfortably operating cash covers total debt obligations.

Medigen Vaccine Biologics Cash Flow Quality Index by Year (2021–2021)

Medigen Vaccine Biologics cash flow quality index by year from 2021 to 2021. Year-by-year earnings quality comparison for Medigen Vaccine Biologics. For the full cash flow conversion analysis, see 6547 cash flow metrics.

Year Quality Index Operating CF (TWD) Net Income YoY Change
2021 0.41x NT$579.89 Million NT$1.41 Billion —
Cash Flow Quality Index = Operating Cash Flow / Net Income. Ratios above 1.0x indicate cash-backed earnings.